Supriya Lifescience Limited

BSE: SUPRIYA543434ISIN INE07RO01027

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹860.70+28.35 (+3.41%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹1,085.50
52W low: ₹545.65
Off 52W high: -20.71%
1M return: -4.34%
3M return: -5.89%
6M return: +22.35%
1Y return: +8.09%
20D avg volume: 9,530
50 DMA: ₹877.38
200 DMA: ₹787.01

Key ratios Standalone

Market cap: ₹6,927 Cr
Current price: ₹860.70
52W high / low: ₹1,085.50 / ₹545.65
Face value: ₹2.00
P/E: 34.92
P/B: 7.65
EPS (TTM): ₹24.65
Book value / share: ₹112.51
ROE: 21.90%
ROCE: 22.40%
Operating margin: 26.41%
Net margin: 12.67%
Debt / equity: 0.00
Net debt: ₹-37.55 Cr
Interest cover: 146.39
Dividend yield: 0.12%
Dividend / share (TTM): ₹1.00
Payout: 4.06%
Cash conversion cycle: 118.3 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	189.75	276.53	206.44	199.83	145.07	184.11	185.65	166.10	160.63	158.18	140.07	140.09
	2.65	3.48	2.61	2.73	2.67	2.98	2.10	2.52	2.22	2.19	3.06	2.47
	192.40	280.01	209.05	202.56	147.75	187.08	187.75	168.62	162.85	160.37	143.14	142.56
	151.60	187.88	141.67	134.24	100.34	123.02	125.17	106.56	103.08	107.19	103.04	112.78
	109.40	83.36	77.30	60.68	43.78	101.53	13.60	61.58	55.73	48.36	44.84	50.70
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	28.49	24.82	24.69	24.48	22.69	20.98	19.77	19.68	20.08	17.14	17.56	17.50
	0.37	0.47	0.49	0.41	0.51	0.42	0.51	0.43	0.34	0.60	0.49	0.46
	8.94	8.50	6.82	6.64	6.45	6.08	4.96	4.74	4.66	3.91	3.96	3.98
	57.41	48.77	48.46	46.98	38.91	40.72	38.14	35.73	29.40	27.27	26.40	29.20
	40.79	92.13	67.38	68.32	47.41	64.06	62.58	62.06	59.77	53.17	40.10	29.78
	0.00	0.00	-0.46	0.00	0.00	0.00	—	—	—	—	—	—
	40.79	92.13	66.92	68.32	47.41	64.06	62.58	62.06	59.77	53.17	40.10	29.78
	16.75	17.90	17.25	17.89	12.62	13.68	15.80	15.91	15.13	16.24	10.31	5.89
	24.04	74.23	49.67	50.43	34.79	50.38	46.78	46.15	44.64	36.93	29.79	23.88
	2.99	9.22	6.17	6.27	4.32	6.29	5.82	5.71	5.54	4.59	3.70	2.97
Key metrics
	50.10	101.10	74.23	75.37	54.37	70.56	68.05	67.23	64.77	57.68	44.55	34.22
	26.40%	36.60%	36.00%	37.70%	37.50%	38.30%	36.70%	40.50%	40.30%	36.50%	31.80%	24.40%
	12.70%	26.80%	24.10%	25.20%	24.00%	27.40%	25.20%	27.80%	27.80%	23.30%	21.30%	17.00%
	—	7.50%	—	6.10%	—	6.30%	—	—	—	—	—	—
	30.80%	50.20%	11.20%	20.30%	-9.70%	16.40%	32.50%	18.60%	—	—	—	—
	-30.90%	47.30%	6.20%	9.30%	-22.10%	36.40%	57.00%	93.30%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	872.55	827.88	696.49	570.37	460.94	530.05
	11.47	11.49	9.81	10.63	9.49	7.58
	884.02	839.36	706.30	581.00	470.43	537.63
	615.39	564.12	457.82	415.31	346.94	330.38
	330.74	265.12	232.44	191.43	187.32	198.83
	0.00	0.00	0.00	—	—	—
	102.48	96.68	80.52	67.64	55.58	49.08
	1.74	1.89	1.69	2.11	3.08	4.20
	30.90	28.41	20.44	15.81	11.81	10.12
	201.62	183.12	143.99	108.02	95.65	—
	268.62	275.24	248.48	165.69	123.49	207.25
	-0.46	-0.46	0.00	—	—	—
	268.16	274.78	248.48	165.69	123.49	207.25
	69.79	65.66	60.52	46.58	33.63	55.44
	198.37	209.12	187.96	119.11	89.86	151.81
	24.65	25.98	23.35	14.80	11.16	18.86
Key metrics
	300.80	305.08	270.61	183.61	138.38	221.57
	34.47%	36.90%	38.90%	32.20%	30.00%	41.80%
	22.73%	25.30%	27.00%	20.90%	19.50%	28.60%
	—	22.40%	24.30%	—	—	—
	28.14%	18.90%	22.10%	23.70%	-13.00%	—
	11.38%	11.30%	57.80%	32.60%	-40.80%	—
	—	33.53	2.30	—	—	—
	—	0.89	0.88	—	—	—
	—	0.00	0.00	—	—	—
	—	-37.55	-76.06	—	—	—
	—	118.3	132.4	—	—	—
Balance sheet
	—	1,357	1,112	—	—	—
	—	532.30	437.04	—	—	—
	—	37.55	76.06	—	—	—
	—	219.45	134.36	—	—	—
	—	159.60	118.35	—	—	—
	—	73.82	103.53	—	—	—
	—	683.32	451.48	—	—	—
	—	110.85	0.00	—	—	—
	—	121.04	82.16	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	1,198	996.76	—	—	—
Cash flow
	—	185.77	164.68	—	—	—
	—	-176.17	-152.25	—	—	—
	—	-9.88	-8.23	—	—	—
	—	152.24	162.38	—	—	—

Compounded growth

Sales CAGR 3Y: +21.56%
Sales CAGR 5Y: —
Profit CAGR 3Y: +32.52%
Profit CAGR 5Y: —
Sales YoY (TTM): +28.14%
Profit YoY (TTM): +11.38%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 68.30%

Quarter	September 2026	June 2026
Promoter %	68.30%	68.30%

Holder	Type	Holding	Previous	Change
Satish Waman Wagh	Promoter	67.64%	67.64%	0.00%
COHESION MK BEST IDEAS SUB-TRUST	Public	3.17%	2.98%	+0.19%
ADITYA BIRLA SUN LIFE INSURANCE COMPANY LIMITED	Public	2.16%	2.19%	-0.03%
Smita Satish Wagh	Promoter Group	0.40%	0.40%	0.00%
Saloni Satish Wagh	Promoter Group	0.13%	0.13%	0.00%
Shivani Satish Wagh	Promoter Group	0.13%	0.13%	0.00%
Satish Waman Wagh Partner representing SupriyaPharmaceuticals	Promoter Group	0.00%	0.00%	0.00%
Arun Waman Wagh	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Supriya Lifescience Limited S	6,927	860.70	34.92	22.40%	+28.14% TTM	+11.38% TTM	+8.09%

Filings & corporate actions

Recent announcements

Enclosed herewith is the announcement under Regulation 30 of SEBI (LODR) Regulations, 2015. Kindly take the same on record.2 Nov 2026 · Company Update / General
Enclosed herewith is the intimation of Results Earnings Call.31 Oct 2026 · Company Update / Analyst / Investor Meet
Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve In terms of Regulation ....30 Oct 2026 · Board Meeting / Board Meeting
Enclosed herewith is the announcement under Regulation 30 of SEBI (LODR) Regulations, 2015. Kindly take the same on record.19 Oct 2026 · Company Update / General
Please find enclosed13 Oct 2026 · Company Update / General
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, is enclosed herewith. Kindly take the same on record.12 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Enclosed herewith is the announcement under Regulation 30 of SEBI (LODR) Regulations, 2015. Kindly take the same on record.8 Oct 2026 · Company Update / General
The Intimation of closure of window for trading in securities of the Company by Designated Persons and their Immediate relatives for the quarter and half year ending on September 30, 2026, ....28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Scrutinizer''s Report for 18th Annual General meeting is attached herewith.25 Sep 2026 · AGM/EGM / AGM
Outcome of AGM along with Proceedings, Scrutinizer Report and Voting Results is attached herewith.25 Sep 2026 · AGM/EGM / AGM
Enclosed herewith is the announcement under Regulation 30 of SEBI (LODR), 2015. Kindly take the same on record.23 Sep 2026 · Company Update / General
Intimation of Analyst/Investor Meeting is enclosed.20 Sep 2026 · Company Update / Analyst / Investor Meet
Intimation of Investor/ Analyst Call is enclosed herewith. Kindly take the same on record.11 Sep 2026 · Company Update / Analyst / Investor Meet
Enclosed herewith is the copy of Letter dispatched to shareholders whose email ids are not registered. Kindly take the same on record.2 Sep 2026 · Company Update / General
Enclosed herewith disclosure under Regulation 30.2 Sep 2026 · Company Update / General
Copy of Newspaper Public for dispatch of AGM Notice and Annual Report.2 Sep 2026 · Company Update / Newspaper Publication
Business Responsibility and Sustainability Report for FY 2025-261 Sep 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Notice of 18th AGM of the Company.1 Sep 2026 · AGM/EGM / AGM
Annual Report1 Sep 2026 · Others / Reg. 34 (1) Annual Report
Copy of Newspaper Publication is enclosed.27 Aug 2026 · Company Update / Newspaper Publication
Enclosed herewith is the intimation of record date for determining list of members eligible to receive dividend for FY 2025-26.26 Aug 2026 · Corp. Action / Record Date
Scrutinizer''s Report and Voting Results for Postal ballot conducted by the Company are enclosed herewith.22 Aug 2026 · AGM/EGM / Postal Ballot
Voting Results and Scrutinizer''s Report for the Postal ballot conducted by the Company are enclosed herewith.22 Aug 2026 · AGM/EGM / Postal Ballot
Earnings Call Transcript of the Earning Call for Unaudited Financial Results for quarter ended June 30, 2026 is enclosed.18 Aug 2026 · Company Update / Earnings Call Transcript
Audio Link for outcome of Results Earnings Call for United Financial Results for quarter ended June 30, 2026 is enclosed.14 Aug 2026 · Company Update / Analyst / Investor Meet
Enclosed herewith Copy of Newspaper Publication of Results for quarter ended June 30, 2026.14 Aug 2026 · Company Update / Newspaper Publication
Press Release for Unaudited Financial Results for quarter ended June 30, 2026 is enclosed herewith.13 Aug 2026 · Company Update / Press Release / Media Release
Investor Presentation for Results Earnings Call for Unaudited Financial Results for quarter ended June 30,2026 is enclosed herewith.13 Aug 2026 · Company Update / Investor Presentation
Unaudited Financial Results for the quarter ended June 30, 2026 is enclosed.13 Aug 2026 · Result / Financial Results
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held ....13 Aug 2026 · Board Meeting / Outcome of Board Meeting
Intimation of the Earnings call for Unaudited Financial Results of the Company for the quarter ended June 30, 2026 is enclosed herewith.10 Aug 2026 · Company Update / Analyst / Investor Meet
Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve In terms of Regulation ....6 Aug 2026 · Board Meeting / Board Meeting
Please find attached copy of Newspaper Publication of Postal Ballot Notice.23 Jul 2026 · Company Update / Newspaper Publication
Please Find Attached Postal Ballot Notice of Supriya Lifescience Limited.21 Jul 2026 · AGM/EGM / Postal Ballot
Enclosed herewith is the Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018, received from RTA.9 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Enclosed herewith is the intimation for submission under Regulation 30 of SEBI (LODR) Regulations, 2015.4 Jul 2026 · Company Update / General
Email Communication to Shareholders regarding Dividend Taxation Provisions.23 Jun 2026 · Company Update / General
Enclosed herewith is the intimation for trading window closure for declaration of Unaudited Financial Results for quarter ending on June 30, 2026.20 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation of Analyst / Investor Meeting is enclosed herewith.15 Jun 2026 · Company Update / Analyst / Investor Meet
Intimation of Investor/Analyst call is enclosed.9 Jun 2026 · Company Update / Analyst / Investor Meet

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 1.0000	4 Sep 2026	4 Sep 2026	—
Final Dividend - Rs. - 1.0000	4 Sep 2025	5 Sep 2025	—
Final Dividend - Rs. - 0.8000	20 Sep 2024	—	—

Board meetings

6 Nov 2026 Board Meeting - Financial Results
13 Aug 2026 Board Meeting - Financial Results